Accelerate blood cancer drug development with our expanded PDX model collection.

Evaluate your therapeutic candidates with our fully annotated models including patient information, diagnosis, and clinical treatments.

Evaluate blood cancer therapeutic candidates with validated, stable, truly patient representative leukemia models.

HuKemia® is Crown Bioscience’s collection of validated blood cancer PDX models, fully annotated with patient information, diagnosis, and clinical treatments. These models have been fully quality controlled by our pathologists and are available with genotyping and phenotyping data.

Advantages of the HuKemia Blood Cancer PDX Collection

Crown Bioscience’s validated and well-characterized HuKemia models provide many advantages:

• Well-established models that have been used in over 100 preclinical studies, and are therefore a tried and tested approach for assessing preclinical efficacy
  
  
• Derived from patients treated with today's clinical therapeutics, including SOC targeted therapies and immunotherapeutics
  
  
• Present as stable disease that is transferable through passages, meaning results are highly reproducible across studies
  
  
• Overcome limitations with CDX models for systemic diseases. When utilizing CDX models, it can be highly challenging to detect the leukemic cells in the blood, limiting studies to only monitoring survival
  
  
• Can be repeatedly challenged to mimic clinical therapy and the emergence of resistance, which means that models of resistance can be created for testing next-generation drugs
  
  
• Optional ex vivo assays to leverage access to fresh tumor samples for all AML and ALL models, enabling the assessment of efficient combination and dosing regimens. An illustration of the HuKemia study design followed by ex vivo workflow is shown below

HuKemia Study Design

Explore our Collection

Log in or Register for HuBase™ to explore our HuKemia blood cancer PDX collection